A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

NCT01183858 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche